134 related articles for article (PubMed ID: 22079741)
1. Irreversible electroporation shows efficacy against pancreatic carcinoma without systemic toxicity in mouse models.
José A; Sobrevals L; Ivorra A; Fillat C
Cancer Lett; 2012 Apr; 317(1):16-23. PubMed ID: 22079741
[TBL] [Abstract][Full Text] [Related]
2. Nestin as a novel therapeutic target for pancreatic cancer via tumor angiogenesis.
Yamahatsu K; Matsuda Y; Ishiwata T; Uchida E; Naito Z
Int J Oncol; 2012 May; 40(5):1345-57. PubMed ID: 22246533
[TBL] [Abstract][Full Text] [Related]
3. Adenovirus-mediated eukaryotic initiation factor 4E binding protein-1 in combination with rapamycin inhibits tumor growth of pancreatic ductal adenocarcinoma in vivo.
Mishra R; Miyamoto M; Yoshioka T; Ishikawa K; Matsumura Y; Shoji Y; Ichinokawa K; Itoh T; Shichinohe T; Hirano S; Kondo S
Int J Oncol; 2009 May; 34(5):1231-40. PubMed ID: 19360336
[TBL] [Abstract][Full Text] [Related]
4. Efficient electrogene therapy for pancreatic adenocarcinoma treatment using the bacterial purine nucleoside phosphorylase suicide gene with fludarabine.
Deharvengt S; Rejiba S; Wack S; Aprahamian M; Hajri A
Int J Oncol; 2007 Jun; 30(6):1397-406. PubMed ID: 17487360
[TBL] [Abstract][Full Text] [Related]
5. Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas.
Mees ST; Mardin WA; Sielker S; Willscher E; Senninger N; Schleicher C; Colombo-Benkmann M; Haier J
Ann Surg Oncol; 2009 Aug; 16(8):2339-50. PubMed ID: 19475450
[TBL] [Abstract][Full Text] [Related]
6. Pancreatic tumor sensitivity to plasma L-asparagine starvation.
Dufour E; Gay F; Aguera K; Scoazec JY; Horand F; Lorenzi PL; Godfrin Y
Pancreas; 2012 Aug; 41(6):940-8. PubMed ID: 22513289
[TBL] [Abstract][Full Text] [Related]
7. Suppression of the uPAR-uPA system retards angiogenesis, invasion, and in vivo tumor development in pancreatic cancer cells.
Gorantla B; Asuthkar S; Rao JS; Patel J; Gondi CS
Mol Cancer Res; 2011 Apr; 9(4):377-89. PubMed ID: 21389187
[TBL] [Abstract][Full Text] [Related]
8. Tumor growth suppression in pancreatic cancer by a putative metastasis suppressor gene Cap43/NDRG1/Drg-1 through modulation of angiogenesis.
Maruyama Y; Ono M; Kawahara A; Yokoyama T; Basaki Y; Kage M; Aoyagi S; Kinoshita H; Kuwano M
Cancer Res; 2006 Jun; 66(12):6233-42. PubMed ID: 16778198
[TBL] [Abstract][Full Text] [Related]
9. Dissecting the role of TGF-beta type I receptor/ALK5 in pancreatic ductal adenocarcinoma: Smad activation is crucial for both the tumor suppressive and prometastatic function.
Schniewind B; Groth S; Sebens Müerköster S; Sipos B; Schäfer H; Kalthoff H; Fändrich F; Ungefroren H
Oncogene; 2007 Jul; 26(33):4850-62. PubMed ID: 17297450
[TBL] [Abstract][Full Text] [Related]
10. Irreversible electroporation of the pancreas is feasible and safe in a porcine survival model.
Fritz S; Sommer CM; Vollherbst D; Wachter MF; Longerich T; Sachsenmeier M; Knapp J; Radeleff BA; Werner J
Pancreas; 2015 Jul; 44(5):791-8. PubMed ID: 25931252
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma.
Xue A; Scarlett CJ; Jackson CJ; Allen BJ; Smith RC
Pancreas; 2008 Mar; 36(2):160-7. PubMed ID: 18376307
[TBL] [Abstract][Full Text] [Related]
12. The Trk tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft models of human pancreatic ductal adenocarcinoma.
Miknyoczki SJ; Chang H; Klein-Szanto A; Dionne CA; Ruggeri BA
Clin Cancer Res; 1999 Aug; 5(8):2205-12. PubMed ID: 10473107
[TBL] [Abstract][Full Text] [Related]
13. Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma.
Vogler M; Walczak H; Stadel D; Haas TL; Genze F; Jovanovic M; Bhanot U; Hasel C; Möller P; Gschwend JE; Simmet T; Debatin KM; Fulda S
Cancer Res; 2009 Mar; 69(6):2425-34. PubMed ID: 19258513
[TBL] [Abstract][Full Text] [Related]
14. The use of IRE in multi-modality treatment for oligometastatic pancreatic cancer.
Hong Y; Rice J; Sharma D; Martin RCG
Am J Surg; 2018 Jul; 216(1):106-110. PubMed ID: 29506753
[TBL] [Abstract][Full Text] [Related]
15. A Syngeneic Pancreatic Cancer Mouse Model to Study the Effects of Irreversible Electroporation.
Shankara Narayanan JS; Ray P; Naqvi I; White R
J Vis Exp; 2018 Jun; (136):. PubMed ID: 29939178
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous Delivery of Dual Inhibitors of DNA Damage Repair Sensitizes Pancreatic Cancer Response to Irreversible Electroporation.
Long X; Dai A; Huang T; Niu W; Liu L; Xu H; Yin T; Jiang T; Sun S; Lei P; Li C; Zhu X; Zhao J
ACS Nano; 2023 Jul; 17(13):12915-12932. PubMed ID: 37352467
[TBL] [Abstract][Full Text] [Related]
17. Interstitial chemotherapy with ricin-loaded thermosensitive hydrogel in pancreatic cancer xenograft.
Chen ZK; Lin LW; Weng XH; Xue ES; Lin YH
Hepatobiliary Pancreat Dis Int; 2009 Aug; 8(4):418-23. PubMed ID: 19666413
[TBL] [Abstract][Full Text] [Related]
18. Irreversible Electroporation for Locally Advanced Pancreatic Cancer.
Timmer FEF; Geboers B; Ruarus AH; Schouten EAC; Nieuwenhuizen S; Puijk RS; de Vries JJJ; Meijerink MR; Scheffer HJ
Tech Vasc Interv Radiol; 2020 Jun; 23(2):100675. PubMed ID: 32591191
[TBL] [Abstract][Full Text] [Related]
19. Broad-spectrum G protein-coupled receptor antagonist, [D-Arg1,D-Trp5,7,9,Leu11]SP: a dual inhibitor of growth and angiogenesis in pancreatic cancer.
Guha S; Eibl G; Kisfalvi K; Fan RS; Burdick M; Reber H; Hines OJ; Strieter R; Rozengurt E
Cancer Res; 2005 Apr; 65(7):2738-45. PubMed ID: 15805273
[TBL] [Abstract][Full Text] [Related]
20. Tumor growth suppression by adenovirus-mediated introduction of a cell-growth-suppressing gene tob in a pancreatic cancer model.
Yanagie H; Tanabe T; Sumimoto H; Sugiyama H; Matsuda S; Nonaka Y; Ogiwara N; Sasaki K; Tani K; Takamoto S; Takahashi H; Eriguchi M
Biomed Pharmacother; 2009 May; 63(4):275-86. PubMed ID: 18657378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
